ABBV - AbbVie Inc.

NYSE - NYSE Delayed Price. Currency in USD
81.15
-0.44 (-0.54%)
At close: 4:01PM EDT

80.00 -1.15 (-1.42%)
Pre-Market: 7:09AM EDT

Stock chart is not supported by your current browser
Previous Close81.59
Open80.39
Bid79.80 x 800
Ask0.00 x 800
Day's Range80.32 - 81.63
52 Week Range75.62 - 103.16
Volume3,136,155
Avg. Volume5,615,622
Market Cap119.966B
Beta (3Y Monthly)0.97
PE Ratio (TTM)23.11
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield4.28 (5.39%)
Ex-Dividend Date2019-04-12
1y Target EstN/A
Trade prices are not sourced from all markets
  • J&J's Invokana sNDA Gets Priority Review Status From FDA
    Zacks23 hours ago

    J&J's Invokana sNDA Gets Priority Review Status From FDA

    FDA grants priority review to J&J's (JNJ) Invokana sNDA for the treatment of chronic kidney disease in patients with type II diabetes

  • Lilly's Crohn's Disease Candidate Meets Phase II Study Goals
    Zacks2 days ago

    Lilly's Crohn's Disease Candidate Meets Phase II Study Goals

    Lilly's (LLY) mirikizumab met primary endpoint and key secondary endpoints in phase II Crohn's disease study.

  • 3 Top Dividend Stocks With Yields Over 5%
    Motley Fool2 days ago

    3 Top Dividend Stocks With Yields Over 5%

    They combine hefty yields with a good shot at significant price appreciation.

  • Top Ranked Income Stocks to Buy for May 22nd
    Zacks2 days ago

    Top Ranked Income Stocks to Buy for May 22nd

    Top Ranked Income Stocks to Buy for May 22nd

  • Go Beyond Bargains: Play 5 Stocks With Rising P/E Instead
    Zacks2 days ago

    Go Beyond Bargains: Play 5 Stocks With Rising P/E Instead

    Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

  • Top Marijuana Stocks That Pay Dividends
    Investopedia3 days ago

    Top Marijuana Stocks That Pay Dividends

    When most people think of marijuana stocks, the last thing they think of is dividends. The legal marijuana industry is still very young, and new companies in growing industries need money to expand. Furthermore, U.S. investors in the marijuana space tend to currently focus on a handful of Canadian companies which have enjoyed the opportunity to list on U.S. exchanges.

  • Better Buy: AbbVie vs. Pfizer
    Motley Fool3 days ago

    Better Buy: AbbVie vs. Pfizer

    AbbVie and Pfizer are both undergoing a radical makeover. Which company should investors trust to come out even stronger?

  • Top Ranked Income Stocks to Buy for May 21st
    Zacks3 days ago

    Top Ranked Income Stocks to Buy for May 21st

    Top Ranked Income Stocks to Buy for May 21st

  • 3 Top Dividend Stocks to Buy Right Now
    Motley Fool3 days ago

    3 Top Dividend Stocks to Buy Right Now

    If you are looking for income stocks, these high yielders are ripe for the picking.

  • Drugmakers’ lobbying spending at 10-year high as Washington targets soaring prices
    MarketWatch4 days ago

    Drugmakers’ lobbying spending at 10-year high as Washington targets soaring prices

    The spending by the industry’s main trade group and seven key drugmakers has climbed to a level not seen in a decade.

  • AbbVie's Brain Cancer Candidate Fails in Phase III Study
    Zacks4 days ago

    AbbVie's Brain Cancer Candidate Fails in Phase III Study

    AbbVie's (ABBV) phase III study on Depatux-M, an investigational candidate for newly diagnosed glioblastoma, fails to show survival benefit in patients receiving Depatux-M.

  • Top 5 New Drug Launches of 2019 -- and the Biotech Stocks That Could Win Big
    Motley Fool5 days ago

    Top 5 New Drug Launches of 2019 -- and the Biotech Stocks That Could Win Big

    These drugs and the biotechs that make them could be on the way to tremendous success in the near future.

  • Roche Gets FDA Nod for Venclexta Plus Gazyva to Treat CLL
    Zacks7 days ago

    Roche Gets FDA Nod for Venclexta Plus Gazyva to Treat CLL

    Roche (RHHBY) gains an FDA nod for the sNDA of its leukemia drug, Venclexta, in combination with Gazyva for the treatment of previously untreated chronic lymphocytic leukemia.

  • AbbVie halts enrollment after brain cancer trial misses goal, shares fall
    Reuters7 days ago

    AbbVie halts enrollment after brain cancer trial misses goal, shares fall

    An independent data monitoring committee recommended the study be stopped due to "lack of survival benefit" for patients receiving the treatment Depatux-M when compared with a placebo, AbbVie said. Depatux-M, when added to the standard regimen of radiation and temozolomide, failed to meet the main goal of achieving overall survival in newly diagnosed patients when compared to patients given a placebo along with radiation and temozolomide. The trial has been testing the drug to treat an aggressive form of brain cancer known as glioblastoma.

  • MarketWatch7 days ago

    AbbVie stock down 1.8% in premarket trade after failure of glioblastoma drug trial

    Shares of AbbVie Inc. fell 1.8% in premarket trade after the company announced that interim data from a Phase 3 trial of glioblastoma drug Depatux-M did not show any survival benefit to patients. An independent monitoring committee recommended stopping the trial, which was conducted in collaboration with the RTOG Foundation, a not-for-profit cancer research organization. "Glioblastoma patients and their caregivers face a devastating disease for which there are few therapeutic options. While we are disappointed that Depatux-M did not demonstrate a survival benefit in the INTELLANCE-1 study, we remain committed to discovering and developing therapies to address some of the most debilitating cancers," said Michael Severino, vice chairman and president of AbbVie, in a statement. AbbVie has halted enrollment in all of its Depatux-M studies. Shares of the company have fallen 14% in the year to date through Thursday, while the S&P 500 has gained 14.7%.

  • Pharma Stock Roundup: FDA Okays Line Extensions of LLY, PFE, ABBV Cancer Drugs
    Zacks7 days ago

    Pharma Stock Roundup: FDA Okays Line Extensions of LLY, PFE, ABBV Cancer Drugs

    FDA grants approval for line extensions of Lilly (LLY), Pfizer (PFE) and Roche (RHHBY)/AbbVie's (ABBV) cancer drugs

  • Why AbbVie (ABBV) is a Great Dividend Stock Right Now
    Zacks9 days ago

    Why AbbVie (ABBV) is a Great Dividend Stock Right Now

    Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

  • 3 Reasons Why AbbVie (ABBV) Is a Great Growth Stock
    Zacks9 days ago

    3 Reasons Why AbbVie (ABBV) Is a Great Growth Stock

    AbbVie (ABBV) possesses solid growth attributes, which could help it handily outperform the market.

  • AbbVie Settles Humira Litigation With Boehringer Ingelheim
    Zacks9 days ago

    AbbVie Settles Humira Litigation With Boehringer Ingelheim

    AbbVie (ABBV) resolves its litigation with Boehringer Ingelheim over U.S. patents for its blockbuster rheumatoid arthritis drug, Humira.

  • Reuters9 days ago

    PRESS DIGEST -Wall Street Journal - May 15

    The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy. - Walt Disney Co moved to take full control over Hulu through ...

  • Investing.com10 days ago

    AbbVie Rises 3%

    Investing.com - AbbVie (NYSE:ABBV) rose by 3.01% to trade at $79.185 by 14:42 (18:42 GMT) on Tuesday on the NYSE exchange.

  • Here are the stocks to buy if an all-out U.S.-China trade war erupts, says Goldman
    MarketWatch10 days ago

    Here are the stocks to buy if an all-out U.S.-China trade war erupts, says Goldman

    As uncertainty over the outcome of Sino-American trade talks grows, so does the possibility of a longer-than-expected negotiations or an all-out trade war, strategists at Goldman Sachs are providing some timely trading strategies.

  • MarketWatch10 days ago

    AbbVie stock up 1.3% after announcing resolution to litigation over Humira in the U.S.

    Shares of AbbVie Inc. rose 1.3% in premarket trade Tuseday after the company announced it had resolved its litigation with biosimilar drugmaker Boehringer Ingelheim over U.S. patents for the rheumatoid arthritis drug Humira. Under the terms of the resolution, AbbVie will grant Boehringer a non-exclusive license to its Humira-related intellectual property in the U.S., which will begin in 2023. Boehringer, which is looking to sell a biosimilar version of Humira in the U.S. called Cyltezo, will pay royalties to AbbVie for licensing the patents. AbbVie will not make any payments to Boehringer. Shares of AbbVie have declined 5% so far this year, while the S&P 500 has gained 12%.

  • MoneyShow11 days ago

    AbbVie- Unique Mix of Growth, Yield and Value

    AbbVie (ABBV) -- spun off from Abbott Labs (ABT) in 2013 -- is a biotechnology company that is focused on the development and commercializing of treatments in immunology, virology, and oncology, notes Ben Reynolds, editor of Sure Dividend.